{ "brief_id": "SPR-2026-0E36", "generated_at": "2026-07-20", "domains": [ "Chemical Biology", "Systems Biology" ], "original_hypothesis": "Activity-based chemical probes from chemical biology can be used as targeted, dynamic, and spatially resolved inputs to experimentally perturb and map the causal structure of biological networks in systems biology.", "grounding": { "novelty_assessment": { "score": 0.85, "closest_existing_work": [ { "paper_id": "0aca68b2f5922b5c02d4d4fe138430fde9a05499", "title": "Empirical inference of circuitry and plasticity in a kinase signaling network", "doi": "10.1073/pnas.1423344112", "year": 2015, "similarity": "related", "key_difference": "This paper uses pharmacological inhibitors (kinase inhibitors) as perturbations to infer network topology, but does not use activity-based probes (ABPs) that covalently bind only the active form of enzymes. The hypothesis proposes ABPs as a more specific, activity-dependent perturbation tool, which is a methodological refinement not demonstrated here.", "authors": [ "E. Wilkes", "Camille Terfve", "J. Gribben", "J. Saez-Rodriguez", "P. Cutillas" ] }, { "paper_id": "b43e97cba1389b70ae218b1608117524f15ef7e8", "title": "A large-scale benchmark for network inference from single-cell perturbation data", "doi": "10.1038/s42003-025-07764-y", "year": 2025, "similarity": "related", "key_difference": "This paper uses genetic perturbations (CRISPR) for causal network inference, not chemical perturbations. The hypothesis specifically proposes chemical biology probes as a complementary approach with different advantages (temporal control, reversibility, activity-dependence), which is not addressed here.", "authors": [ "Mathieu Chevalley", "Yusuf H. Roohani", "Arash Mehrjou", "J. Leskovec", "Patrick Schwab" ] }, { "paper_id": "47a5a68c9c6d590af66d53f4dd2b25dae86f4515", "title": "Concurrent TMS-fMRI for causal network perturbation and proof of target engagement", "doi": "10.1016/j.neuroimage.2021.118093", "year": 2021, "similarity": "analogous", "key_difference": "This paper uses neurostimulation (TMS) for causal perturbation in neuroscience, which is conceptually analogous but in a different domain (neuroscience vs. molecular/cellular biology). The hypothesis applies the same logic to chemical biology probes in molecular networks.", "authors": [ "T. Bergmann", "R. Varatheeswaran", "C. Hanlon", "Kristoffer Hougaard Madsen", "A. Thielscher", "H. Siebner" ] } ], "verdict": "novel" }, "evidence_base": [ { "paper_id": "dfac42a62cbf8ac9e1c53673cd16fd442cadc1d3", "title": "Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity", "doi": "10.1021/jacs.0c04527", "year": 2019, "citation_count": 68, "support_type": "direct", "relevance": "Directly demonstrates the design and application of an activity-based probe (ABP) that covalently and selectively binds to the active form of a specific enzyme (UCHL1). This is the core chemical biology tool the hypothesis relies on.", "key_finding": "IMP-1710 is a potent and selective covalent inhibitor/ABP for UCHL1 that labels the catalytic cysteine at low nanomolar concentrations in intact cells.", "authors": [ "Nattawadee Panyain", "A. Godinat", "Thomas Lanyon-Hogg", "Sofía Lachiondo‐Ortega", "Edward J Will", "C. Soudy", "M. Mondal", "Katie Mason", "S. Elkhalifa", "Lisa M. Smith", "J. Harrigan", "Edward W. Tate" ] }, { "paper_id": "b2fd153913143a5824fdfe1ad5c48ae0c1775ced", "title": "A cathepsin targeted quenched activity-based probe facilitates enhanced detection of human tumors during resection", "doi": "10.1158/1078-0432.CCR-22-1215", "year": 2022, "citation_count": 30, "support_type": "direct", "relevance": "Shows clinical translation of an ABP (VGT-309) that targets cathepsins, demonstrating that ABPs can be used in vivo for specific, activity-dependent labeling. Supports the feasibility of using ABPs as perturbations in living systems.", "key_finding": "VGT-309, a cathepsin-targeted quenched ABP, safely and specifically labels human pulmonary tumors during resection, demonstrating in vivo utility.", "authors": [ "G. Kennedy", "David E Holt", "F. Azari", "E. Bernstein", "B. Nadeem", "A. Chang", "Neil T. Sullivan", "Alix Segil", "C. Deshpande", "E. Bensen", "J. Santini", "J. Kucharczuk", "E. Delikatny", "M. Bogyo", "A. Egan", "Charles W. Bradley", "E. Eruslanov", "J. Lickliter", "Gavin Wright", "S. Singhal" ] }, { "paper_id": "0c702adca00c5308cb355cd752615f3ad0801beb", "title": "Quantitative metaproteomics and activity-based probe enrichment reveals significant alterations in protein expression from a mouse model of inflammatory bowel disease", "doi": "10.1021/acs.jproteome.6b00938", "year": 2017, "citation_count": 59, "support_type": "indirect", "relevance": "Combines ABPs with quantitative proteomics (metaproteomics) to study a biological system. This is methodologically similar to the proposed 'chemically triggered perturbation-omics' platform, though the focus is on enrichment/detection rather than perturbation for causal inference.", "key_finding": "ABPs can enrich and analyze both host and microbial proteins with specificity in a complex in vivo system (mouse model of IBD).", "authors": [ "Michael Mayers", "Clara Moon", "Gregory S. Stupp", "Andrew I. Su", "D. Wolan" ] }, { "paper_id": "880ba3c17706f0c2c023ac154e8436cfee1a087a", "title": "Activity-based profiling of cullin–RING E3 networks by conformation-specific probes", "doi": "10.1038/s41589-023-01392-5", "year": 2023, "citation_count": 21, "support_type": "indirect", "relevance": "Develops probes that specifically recognize the active conformation of CRL complexes. This is an advanced form of activity-based probing that could be adapted for perturbation experiments to map network topology.", "key_finding": "Conformation-specific antibodies (probes) were developed to profile activated cullin-RING E3 ligase networks in response to stimuli and drugs.", "authors": [ "L. T. Henneberg", "Jaspal Singh", "David M. Duda", "Kheewoong Baek", "David Yanishevski", "P. J. Murray", "Matthias Mann", "S. Sidhu", "B. Schulman" ] }, { "paper_id": "0aca68b2f5922b5c02d4d4fe138430fde9a05499", "title": "Empirical inference of circuitry and plasticity in a kinase signaling network", "doi": "10.1073/pnas.1423344112", "year": 2015, "citation_count": 72, "support_type": "indirect", "relevance": "Demonstrates the systems biology goal of inferring network topology from perturbation experiments (using kinase inhibitors). Supports the feasibility of the overall approach, though the perturbations used are not ABPs.", "key_finding": "Kinase signaling network topology can be inferred de novo from MS-based phosphoproteomics data following pharmacological perturbations.", "authors": [ "E. Wilkes", "Camille Terfve", "J. Gribben", "J. Saez-Rodriguez", "P. Cutillas" ] }, { "paper_id": "b43e97cba1389b70ae218b1608117524f15ef7e8", "title": "A large-scale benchmark for network inference from single-cell perturbation data", "doi": "10.1038/s42003-025-07764-y", "year": 2025, "citation_count": 35, "support_type": "indirect", "relevance": "Provides a benchmark for causal network inference from perturbation data, validating the systems biology methodology that the hypothesis aims to enhance with ABPs.", "key_finding": "CausalBench provides a standardized framework for evaluating network inference methods using real-world perturbation data.", "authors": [ "Mathieu Chevalley", "Yusuf H. Roohani", "Arash Mehrjou", "J. Leskovec", "Patrick Schwab" ] }, { "paper_id": "55524233899b3240f3e242423cfda97db9af7834", "title": "Thiomethyltetrazines are Reversible Covalent Cysteine Warheads whose Dynamic Behavior can be “Switched Off” via Bioorthogonal Chemistry Inside Live Cells", "doi": "10.1021/jacs.3c04444", "year": 2023, "citation_count": 21, "support_type": "indirect", "relevance": "Introduces a bioorthogonal 'switch' to lock in covalent modifications. This provides a chemical tool that could be used to create temporally controlled perturbations (e.g., turn on/off inhibition), which is a key aspect of the hypothesis.", "key_finding": "Thiomethyltetrazines act as reversible covalent warheads that can be 'locked' via bioorthogonal Diels-Alder chemistry inside live cells.", "authors": [ "Amanda M. Tallon", "Yingrong Xu", "Graham M. West", "Christopher W. am Ende", "Joseph M. Fox" ] }, { "paper_id": "e41282ccb4f4dd8677b5b72321de11564db0565e", "title": "Dual-Reactivity trans-Cyclooctenol Probes for Sulfenylation in Live Cells Enable Temporal Control via Bioorthogonal Quenching", "doi": "10.1021/jacs.9b01164", "year": 2019, "citation_count": 37, "support_type": "indirect", "relevance": "Demonstrates temporal control of probe reactivity via bioorthogonal quenching. This supports the hypothesis's claim that ABPs can provide time-controlled perturbations.", "key_finding": "SAM-TCO probes enable temporal control of sulfenic acid labeling via bioorthogonal quenching in live cells.", "authors": [ "Samuel L. Scinto", "Oshini Ekanayake", "Uthpala I. Seneviratne", "Jessica E. Pigga", "Samantha J. Boyd", "Michael T. Taylor", "Jun Liu", "Christopher W. am Ende", "S. Rozovsky", "J. Fox" ] } ], "counter_evidence": [ { "paper_id": "835de5f009e82d7344540cdf8c62db91426db64f", "title": "Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target", "doi": "10.3762/bjoc.9.3", "year": 2013, "citation_count": 33, "finding": "A supposedly specific covalent inhibitor (K777 analogue) was found to have an off-target (TcCYP51) that was actually responsible for its primary activity. This highlights the risk of off-target effects with covalent probes, which could confound causal inference in the proposed platform.", "severity": "serious", "authors": [ "J. Choy", "Clifford Bryant", "C. M. Calvet", "P. Doyle", "Shamila S. Gunatilleke", "S. Leung", "K. Ang", "Steven Chen", "J. Gut", "J. Oses-Prieto", "J. B. Johnston", "M. Arkin", "A. Burlingame", "J. Taunton", "M. Jacobson", "J. McKerrow", "L. Podust", "A. Renslo" ] }, { "paper_id": "0aca68b2f5922b5c02d4d4fe138430fde9a05499", "title": "Empirical inference of circuitry and plasticity in a kinase signaling network", "doi": "10.1073/pnas.1423344112", "year": 2015, "citation_count": 72, "finding": "The study observed stochasticity in network remodeling upon chronic inhibition, suggesting that even with specific perturbations, the system's response can be variable and not deterministic. This could complicate causal inference from single perturbation experiments.", "severity": "addressable", "authors": [ "E. Wilkes", "Camille Terfve", "J. Gribben", "J. Saez-Rodriguez", "P. Cutillas" ] } ], "gap_manifest_update": { "closed_gaps": [ "The data_gap regarding lack of knowledge of current methodological bottlenecks in causal network inference is partially closed by paper b43e97cba1389b70ae218b1608117524f15ef7e8, which provides a benchmark for perturbation-based network inference.", "The competence_gap regarding throughput/cost of multi-omics experiments is partially addressed by paper 0aca68b2f5922b5c02d4d4fe138430fde9a05499, which demonstrates the feasibility of combining perturbations with MS-based proteomics for network inference." ], "new_gaps": [ "The counter_evidence from paper 835de5f009e82d7344540cdf8c62db91426db64f reveals a critical gap: the potential for off-target effects of ABPs to confound causal inference. The hypothesis must address how to validate target specificity in the proposed platform.", "The counter_evidence from paper 0aca68b2f5922b5c02d4d4fe138430fde9a05499 reveals a gap in understanding how stochasticity in network remodeling might affect the reproducibility and interpretability of causal inference from single ABP perturbations." ], "data_available": [ "Paper b43e97cba1389b70ae218b1608117524f15ef7e8 provides a benchmark dataset (CausalBench) for evaluating network inference methods from perturbation data.", "Paper 0aca68b2f5922b5c02d4d4fe138430fde9a05499 provides a dataset of phosphoproteomic responses to kinase inhibitor perturbations." ] }, "search_queries": [ { "query": "activity-based probes causal inference networks", "type": "novelty", "rationale": "Direct search for the core hypothesis combining ABPs with causal network inference" }, { "query": "chemical perturbation multi-omics causal structure", "type": "novelty", "rationale": "Checks if chemically triggered perturbation-omics platforms for causal mapping exist" }, { "query": "activity-based probes systems biology perturbation", "type": "novelty", "rationale": "Verifies if ABPs are explicitly used as systems biology perturbation tools beyond detection" }, { "query": "covalent inhibitor network topology inference", "type": "novelty", "rationale": "Tests if covalent inhibitors (like ABPs) are applied to infer network topology" }, { "query": "activity-based probe enzyme inhibition proteomics", "type": "evidence", "rationale": "Finds evidence for ABP specificity and covalent binding to active enzymes" }, { "query": "bioorthogonal labeling temporal perturbation signaling", "type": "evidence", "rationale": "Searches for evidence of time-controlled perturbations using bioorthogonal chemistry" }, { "query": "chemical genetics causal inference transcriptomics", "type": "evidence", "rationale": "Looks for evidence of chemical genetics approaches for causal inference from omics data" }, { "query": "targeted protease inhibitor metabolomics flux", "type": "evidence", "rationale": "Finds evidence for using targeted enzyme inhibitors to perturb metabolic fluxes" }, { "query": "optogenetics perturbation causal network mapping", "type": "cross_domain", "rationale": "Explores precedents from optogenetics for dynamic, spatially resolved perturbation in systems biology" }, { "query": "chemogenomics kinase inhibitor network inference", "type": "cross_domain", "rationale": "Searches for interdisciplinary precedents using chemogenomic libraries for network mapping" }, { "query": "CRISPR perturbation multi-omics causal modeling", "type": "cross_domain", "rationale": "Finds precedents from CRISPR-based perturbation-omics for causal inference, analogous to ABP approach" } ] }, "sharpened": { "title": "Activity-Based Probes as Causal Perturbagens for Dynamic Inference of Enzyme Network Topology in Live Cells", "formal_statement": "If a cell-permeable, covalent activity-based probe (ABP) targeting a specific enzyme family is applied at a concentration that achieves ≥90% target occupancy within 15 minutes, then the resulting multi-omics perturbation response (transcriptomics, proteomics, metabolomics) will enable the inference of causal edges in the target's signaling network with a precision-recall AUC ≥ 0.75, because the ABP's activity-dependent, irreversible binding creates a temporally precise and specific node inhibition that allows for the deconvolution of direct from indirect regulatory effects via differential equation modeling of the time-resolved omics data.", "independent_variables": [ { "name": "ABP concentration", "type": "continuous", "range": "0.1 - 10.0", "unit": "µM" }, { "name": "ABP incubation time", "type": "continuous", "range": "0 - 120", "unit": "minutes" }, { "name": "Target enzyme identity", "type": "categorical", "range": "e.g., UCHL1, Cathepsin B, CRL E3 ligase", "unit": "N/A" } ], "dependent_variables": [ { "name": "Target enzyme residual activity", "type": "continuous", "expected_direction": "decrease", "unit": "% of baseline activity" }, { "name": "Number of differentially expressed proteins (DEPs) at 60 min", "type": "continuous", "expected_direction": "increase", "unit": "count" }, { "name": "Causal network inference precision-recall AUC", "type": "continuous", "expected_direction": "increase", "unit": "AUC (0-1)" }, { "name": "Time to 50% maximal phosphoproteomic response (t_50)", "type": "continuous", "expected_direction": "non-monotonic", "unit": "minutes" } ], "proposed_mechanism": { "causal_chain": [ "Step 1: ABP (e.g., IMP-1710 for UCHL1) is added to live cells at a concentration (e.g., 1 µM) that saturates the active site of the target enzyme within 15 minutes, forming a covalent adduct and reducing its catalytic activity by ≥95%.", "Step 2: The acute loss of target enzyme function disrupts its immediate downstream substrates (e.g., ubiquitin chain processing for UCHL1), causing a rapid accumulation of specific substrate species within 5-10 minutes.", "Step 3: The accumulated substrates trigger compensatory or feed-forward signaling through parallel pathways, leading to a cascade of post-translational modifications (e.g., phosphorylation) and transcriptional changes measurable by phosphoproteomics and RNA-seq at 30-120 minutes.", "Step 4: Time-resolved multi-omics data (e.g., 8 time points over 0-120 min) are used to fit a dynamic Bayesian network or ordinary differential equation model, where the known time of ABP addition serves as a forced intervention node, allowing the algorithm to distinguish causal edges from correlations." ], "key_assumptions": [ "Assumption 1: The ABP is cell-permeable and reaches an intracellular concentration sufficient for target occupancy without significant efflux or metabolism within the experimental window.", "Assumption 2: The ABP has no measurable off-target activity against any other enzyme in the proteome at the working concentration (selectivity >100-fold over the next closest target).", "Assumption 3: The target enzyme's activity is the rate-limiting step for its immediate downstream reactions, such that its inhibition produces a detectable accumulation of substrate within 10 minutes.", "Assumption 4: The biological network is at steady-state prior to perturbation, and the observed omics changes are solely due to the ABP-induced node inhibition, not to cellular stress responses from the vehicle (e.g., DMSO ≤0.1% v/v)." ], "known_unknowns": [ "We do not know whether the off-target profile of a given ABP (e.g., IMP-1710) will be sufficiently clean in a non-human cell line (e.g., HEK293T) to avoid confounding signals.", "We do not know the optimal number of time points or the sampling frequency required to capture the fastest post-translational modification events (e.g., phosphorylation within 1-2 minutes).", "We do not know whether the inferred causal edges will be stable across different cell types or if they are highly context-dependent." ] }, "falsifiable_predictions": [ { "prediction": "Application of 1 µM IMP-1710 to HEK293T cells will reduce UCHL1 activity by ≥95% within 15 minutes, as measured by a fluorogenic substrate assay.", "quantitative_bound": "Residual UCHL1 activity ≤5% of DMSO control at t=15 min.", "measurement_method": "In-cell activity assay using Ub-AMC substrate (ex/em 380/460 nm) on cell lysates.", "null_hypothesis": "H0: Mean residual UCHL1 activity at 15 min is not significantly different from DMSO control (≥90% of control).", "statistical_test": "One-tailed t-test, α=0.01, n=3 biological replicates." }, { "prediction": "The number of differentially expressed proteins (DEPs, fold-change >2, FDR <0.05) at 60 minutes post-IMP-1710 treatment will be at least 50, as measured by TMT-based quantitative proteomics.", "quantitative_bound": "≥50 DEPs identified at 60 min vs. DMSO control.", "measurement_method": "TMT10-plex quantitative proteomics on a Q-Exactive HF-X mass spectrometer.", "null_hypothesis": "H0: The number of DEPs at 60 min does not exceed the number expected by chance (≤5 DEPs).", "statistical_test": "Permutation test (10,000 permutations) on the number of proteins with q<0.05, α=0.05." }, { "prediction": "Causal network inference using the time-resolved phosphoproteomics data (8 time points, 0-120 min) will achieve a precision-recall AUC ≥0.75 when validated against a known gold-standard network for UCHL1 signaling derived from literature-curated interactions.", "quantitative_bound": "PR-AUC ≥0.75 for the inferred network.", "measurement_method": "Dynamic Bayesian network inference (e.g., using the 'CausalBench' framework) on phosphopeptide intensity time series.", "null_hypothesis": "H0: The PR-AUC of the inferred network is not significantly greater than that of a network inferred from randomly permuted time labels (PR-AUC ≤0.50).", "statistical_test": "One-sided Wilcoxon signed-rank test comparing PR-AUC from 10 independent DBN runs vs. 10 runs on permuted data, α=0.05." } ], "boundary_conditions": [ { "condition": "ABP concentration must be ≤10 µM to avoid non-specific thiol reactivity.", "justification": "Above 10 µM, many covalent warheads (e.g., acrylamides) begin to react with off-target cysteines, violating the specificity assumption." }, { "condition": "Cell viability must remain >90% (by MTT assay) throughout the 120-minute experiment.", "justification": "If cell death exceeds 10%, the omics signal will be dominated by apoptosis/necrosis pathways rather than the specific network perturbation." }, { "condition": "The target enzyme must have a known, validated fluorogenic or activity-based substrate for the in-cell activity assay.", "justification": "Without a direct activity readout, target engagement cannot be confirmed, and the causal chain from probe binding to network perturbation is unverifiable." }, { "condition": "The experiment must be performed in a cell line with a sequenced genome and well-annotated proteome (e.g., HEK293T, HeLa).", "justification": "Accurate protein identification and quantification in the omics pipeline requires a high-quality reference database." } ], "theoretical_framework": "Causal inference in biological networks via interventional perturbation-omics" }, "protocol": { "protocol_title": "Validation of Activity-Based Probes as Causal Perturbagens for Dynamic Enzyme Network Inference via Multi-Omics Time-Series", "overall_timeline": "8-14 months", "overall_budget_estimate": "€20k-80k", "phases": [ { "phase_number": 1, "phase_name": "In Silico Validation: Target Engagement, Selectivity, and Network Feasibility", "objective": "To computationally confirm that the chosen ABP (IMP-1710 for UCHL1) can achieve ≥90% target occupancy within 15 minutes at ≤10 µM, has a predicted off-target profile that is clean enough to avoid confounding signals, and that the target enzyme's known interactome is sufficiently large to generate ≥50 DEPs upon perturbation.", "methodology": "1. **Molecular Docking & Covalent Docking**: Use AutoDock Vina with covalent docking module (ADFR) to predict binding pose and binding energy of IMP-1710 to UCHL1 active site (PDB: 3KVF). Simulate occupancy kinetics using a simple ODE model (MATLAB/Python) with kon/koff estimates from literature (e.g., kobs/[I] from [2019] paper). 2. **Off-Target Prediction**: Run the IMP-1710 structure through SwissTargetPrediction, SEA (Similarity Ensemble Approach), and DOCKovalent (for cysteine-reactive warheads). Filter for cysteine-containing proteins with >50% sequence similarity in active site. Generate a list of top 50 predicted off-targets. 3. **Network Topology Analysis**: Query STRING DB, BioGRID, and PhosphoSitePlus for UCHL1 interactors (direct and indirect). Build a literature-curated gold-standard network (≥100 edges). Simulate a 90% inhibition of UCHL1 using a Boolean network model (CellNetOptimizer) to predict the number of DEPs at 60 min. 4. **Time-Series Sampling Feasibility**: Use the simulated data to determine the minimal number of time points needed to capture the fastest phosphorylation events (e.g., 1-2 min) using Nyquist-Shannon sampling theorem. Generate a sampling schedule (e.g., 0, 2, 5, 10, 15, 30, 60, 120 min).", "required_resources": { "equipment": [ "High-performance workstation (64 GB RAM, 8-core CPU, NVIDIA RTX 3080 GPU for docking)" ], "software": [ "AutoDock Vina + ADFR", "MATLAB R2023a or Python 3.10 with SciPy, PySB", "SwissTargetPrediction web server", "SEA web server", "DOCKovalent (UCSF)", "CellNetOptimizer (MATLAB)", "Cytoscape 3.9" ], "datasets": [ "PDB structure 3KVF (UCHL1)", "STRING DB v12.0", "BioGRID v4.4", "PhosphoSitePlus (human phosphorylation sites)", "ChEMBL30 (for off-target profiling)" ], "competences": [ "Computational chemistry (docking)", "Systems biology modeling (ODE/Boolean)", "Bioinformatics (network analysis)", "Python/MATLAB scripting" ], "estimated_cost": "€500-2000", "estimated_duration": "4-6 weeks" }, "expected_outputs": [ "Output 1: Predicted IMP-1710 occupancy kinetics curve showing ≥90% occupancy at 15 min at 1 µM.", "Output 2: Ranked list of top 20 predicted off-targets with estimated IC50 values; confirmation that no off-target has IC50 <10 µM.", "Output 3: Simulated number of DEPs at 60 min under 90% UCHL1 inhibition (should be ≥50).", "Output 4: Optimal time-point sampling schedule (8 time points) for phosphoproteomics." ], "success_criteria": [ { "metric": "Predicted target occupancy at 15 min", "threshold": "≥90% at ≤1 µM IMP-1710", "measurement": "ODE simulation of kon/koff from docking scores and literature kobs" }, { "metric": "Off-target selectivity index", "threshold": "IC50(off-target) / IC50(UCHL1) > 100", "measurement": "Computational prediction from SEA and DOCKovalent" }, { "metric": "Simulated DEP count at 60 min", "threshold": "≥50 DEPs (fold-change >2, FDR <0.05)", "measurement": "Boolean network simulation with 90% UCHL1 inhibition" } ], "go_nogo_decision": { "go_if": "All three success criteria met (occupancy ≥90%, selectivity >100-fold, DEPs ≥50).", "nogo_if": "Any criterion fails (e.g., occupancy <80% at 1 µM, or top off-target IC50 <10 µM, or DEPs <20).", "pivot_if": "If occupancy is borderline (80-90%) but selectivity is excellent, consider increasing ABP concentration to 3 µM (still ≤10 µM). If DEP count is low (<50), consider a different target enzyme (e.g., Cathepsin B) with a larger known interactome." }, "risks": [ { "risk": "Docking predictions may be inaccurate due to protein flexibility or solvation effects.", "probability": "medium", "mitigation": "Use ensemble docking with multiple UCHL1 conformations from MD simulations (e.g., 10 ns GROMACS). Validate with literature kobs from [2019]." }, { "risk": "Off-target predictions may miss non-covalent interactions or allosteric binding.", "probability": "medium", "mitigation": "Cross-validate with DOCKovalent for covalent targets and SwissTargetPrediction for non-covalent. If >10 predicted off-targets with IC50 <10 µM, flag as high risk." }, { "risk": "Boolean network model may oversimplify dynamics, leading to inaccurate DEP predictions.", "probability": "low", "mitigation": "Use a more detailed ODE model (e.g., PySB) with literature-derived rate constants for UCHL1-substrate interactions." } ] }, { "phase_number": 2, "phase_name": "Minimal Experimental Validation: Target Engagement and Immediate Downstream Effects", "objective": "To physically confirm that IMP-1710 achieves ≥95% UCHL1 inhibition within 15 minutes in live HEK293T cells, that cell viability remains >90%, and that the immediate downstream substrate (e.g., ubiquitin-AMC processing) accumulates detectably within 10 minutes.", "methodology": "1. **Cell Culture and Treatment**: Culture HEK293T cells in DMEM + 10% FBS. Treat with 1 µM IMP-1710 (or DMSO 0.1% v/v as control) for 0, 5, 10, 15, 30, 60, 120 min. 2. **In-Cell Activity Assay**: At each time point, lyse cells in ice-cold RIPA buffer (without inhibitors). Measure UCHL1 activity using 10 µM Ub-AMC substrate (Boston Biochem) in a 96-well plate reader (ex/em 380/460 nm) at 37°C for 30 min. Calculate residual activity as % of DMSO control at t=0. 3. **Cell Viability**: Perform MTT assay (Sigma) on parallel wells at 120 min. 4. **Substrate Accumulation**: Use a ubiquitin chain-specific antibody (e.g., anti-K48 ubiquitin, Cell Signaling #4289) to perform Western blot on lysates from 0, 5, 10 min time points. Quantify band intensity for high-molecular-weight ubiquitin conjugates. 5. **Off-Target Check**: Run a small-scale (3-plex TMT) proteomics on 60 min samples vs. DMSO control. Identify proteins with >2-fold change (FDR <0.05) that are not in the UCHL1 interactome (from STRING). If >5 such proteins appear, flag off-target activity.", "required_resources": { "equipment": [ "CO2 incubator", "Biosafety cabinet (Class II)", "96-well plate reader (fluorescence/absorbance)", "Western blot apparatus (gel electrophoresis, transfer, imager)", "Q-Exactive HF-X mass spectrometer (shared facility)" ], "software": [ "GraphPad Prism 10", "MaxQuant v2.4 (for proteomics)", "ImageJ (for Western blot quantification)" ], "datasets": [ "None required beyond Phase 1 outputs" ], "competences": [ "Mammalian cell culture", "Enzyme activity assays (fluorogenic)", "Western blotting", "Basic proteomics sample preparation (TMT labeling)" ], "estimated_cost": "€2k-15k", "estimated_duration": "1-3 months" }, "expected_outputs": [ "Output 1: Time-resolved UCHL1 activity curve showing ≤5% residual activity at 15 min.", "Output 2: Cell viability >90% at 120 min.", "Output 3: Western blot showing ≥2-fold increase in K48-ubiquitin conjugates at 10 min vs. t=0.", "Output 4: List of off-target proteins from 3-plex TMT proteomics (if any)." ], "success_criteria": [ { "metric": "Residual UCHL1 activity at 15 min", "threshold": "≤5% of DMSO control (mean, n=3)", "measurement": "Ub-AMC fluorogenic assay, one-tailed t-test vs. control, α=0.01" }, { "metric": "Cell viability at 120 min", "threshold": ">90% of DMSO control", "measurement": "MTT assay, absorbance at 570 nm" }, { "metric": "K48-ubiquitin conjugate fold-change at 10 min", "threshold": "≥2-fold increase vs. t=0", "measurement": "Western blot band intensity quantification, ImageJ" }, { "metric": "Off-target protein count", "threshold": "≤5 proteins with >2-fold change not in UCHL1 interactome", "measurement": "3-plex TMT proteomics, MaxQuant analysis" } ], "go_nogo_decision": { "go_if": "All four criteria met (activity ≤5%, viability >90%, substrate accumulation ≥2-fold, off-targets ≤5).", "nogo_if": "Activity >10% at 15 min, or viability <85%, or off-targets >10.", "pivot_if": "If activity is 5-10% at 15 min, increase IMP-1710 concentration to 3 µM (still ≤10 µM). If off-targets are 6-10, perform a dose-response (0.1-10 µM) to find a concentration with minimal off-targets while maintaining ≥95% inhibition." }, "risks": [ { "risk": "Ub-AMC assay may not be sensitive enough to detect residual activity in cell lysates.", "probability": "low", "mitigation": "Use a more sensitive activity-based probe (e.g., Cy5-IMP-1710) for in-gel fluorescence detection of active UCHL1." }, { "risk": "K48-ubiquitin accumulation may be transient and missed at 10 min.", "probability": "medium", "mitigation": "Include 2, 5, 7.5 min time points in a pilot experiment. Use a pan-ubiquitin antibody (e.g., FK2) as backup." }, { "risk": "Off-target proteomics may be underpowered with n=1 per condition.", "probability": "medium", "mitigation": "Use n=3 biological replicates for the TMT experiment. If budget is tight, use a single 10-plex TMT with 3 controls and 3 treated samples." } ] }, { "phase_number": 3, "phase_name": "Full Experimental Protocol: Time-Resolved Multi-Omics and Causal Network Inference", "objective": "To generate a high-quality time-resolved multi-omics dataset (transcriptomics, proteomics, phosphoproteomics, metabolomics) from IMP-1710-treated HEK293T cells, and to use these data to infer a causal network for UCHL1 signaling with a precision-recall AUC ≥0.75 against a literature-curated gold standard.", "methodology": "1. **Large-Scale Cell Culture**: Grow HEK293T cells in 15 cm dishes (10 dishes per time point). Treat with 1 µM IMP-1710 (or DMSO 0.1%) for 0, 2, 5, 10, 15, 30, 60, 120 min (8 time points, n=3 biological replicates = 24 samples total). 2. **Sample Collection**: At each time point, wash cells with ice-cold PBS, scrape, and pellet. Split into four aliquots: (a) RNA extraction (TRIzol), (b) protein extraction (8 M urea + phosphatase inhibitors), (c) metabolite extraction (80% methanol), (d) cell viability check (MTT). 3. **Omics Processing**: - **Transcriptomics**: RNA-seq (Illumina NovaSeq 6000, 30M reads/sample). - **Proteomics**: TMT11-plex (3 replicates per time point, 8 time points = 24 samples, use 2 TMT kits). LC-MS/MS on Orbitrap Eclipse. - **Phosphoproteomics**: TiO2 enrichment (GL Sciences) from 1 mg protein per sample. LC-MS/MS on Orbitrap Eclipse. - **Metabolomics**: HILIC-UPLC-MS (Waters Xevo TQ-XS). 4. **Data Analysis**: - **Differential Expression**: DESeq2 (RNA-seq), MaxQuant + Perseus (proteomics/phoshoproteomics), MetaboAnalyst (metabolomics). - **Causal Network Inference**: Use the 'CausalBench' framework (Python) with a Dynamic Bayesian Network (DBN) model. Input: phosphopeptide intensity time series (8 time points). Forced intervention node: IMP-1710 addition at t=0. - **Validation**: Compare inferred edges to the gold-standard network from Phase 1 (literature-curated). Compute precision-recall AUC. 5. **Statistical Power**: With n=3 per time point and 8 time points, we have 80% power to detect a 2-fold change in protein expression (FDR <0.05) for proteins with mean intensity >10^6 (based on pilot data from Phase 2).", "required_resources": { "equipment": [ "Large-scale CO2 incubator (10 x 15 cm dishes)", "Orbitrap Eclipse mass spectrometer (shared facility)", "Illumina NovaSeq 6000 (shared facility)", "Waters Xevo TQ-XS (shared facility)", "TiO2 enrichment columns (GL Sciences)", "SpeedVac concentrator" ], "software": [ "DESeq2 (R)", "MaxQuant v2.4 + Perseus", "MetaboAnalyst 5.0", "CausalBench (Python, GitHub: causalbench/causalbench)", "Cytoscape 3.9 (network visualization)" ], "datasets": [ "Gold-standard UCHL1 network from Phase 1", "HEK293T reference proteome (UniProt UP000005640)" ], "competences": [ "Advanced cell culture (large-scale)", "Multi-omics sample preparation (TMT, TiO2, HILIC)", "LC-MS/MS operation (shared facility)", "Bioinformatics (DBN, network inference)", "Statistical analysis (R/Python)" ], "estimated_cost": "€15k-100k+", "estimated_duration": "6-12 months" }, "expected_outputs": [ "Output 1: Complete multi-omics dataset (RNA-seq, proteomics, phosphoproteomics, metabolomics) for 8 time points, 3 replicates.", "Output 2: List of DEPs, DE phosphopeptides, and DE metabolites at each time point.", "Output 3: Inferred causal network (DBN) with edge weights and confidence scores.", "Output 4: Precision-recall AUC for the inferred network vs. gold standard (target ≥0.75).", "Output 5: Sensitivity analysis: stability of inferred edges across different time-point subsets (e.g., using 6 instead of 8 time points)." ], "success_criteria": [ { "metric": "Precision-recall AUC of inferred network", "threshold": "≥0.75 (mean over 10 independent DBN runs)", "measurement": "CausalBench DBN inference vs. gold-standard network; one-sided Wilcoxon signed-rank test vs. permuted data (α=0.05)" }, { "metric": "Number of DEPs at 60 min (proteomics)", "threshold": "≥50 DEPs (fold-change >2, FDR <0.05)", "measurement": "MaxQuant + Perseus, permutation test (10,000 permutations)" }, { "metric": "Time to 50% maximal phosphoproteomic response (t_50)", "threshold": "≤30 min (non-monotonic expected)", "measurement": "Fit sigmoidal curve to median phosphopeptide intensity across time points" } ], "go_nogo_decision": { "go_if": "PR-AUC ≥0.75 and DEP count ≥50 and t_50 ≤30 min.", "nogo_if": "PR-AUC <0.60 or DEP count <20.", "pivot_if": "If PR-AUC is 0.60-0.75, try alternative network inference methods (e.g., SINCERITIES, GENIE3) or include metabolomics data as additional features. If DEP count is 20-50, extend time course to 180 min to capture later transcriptional changes." }, "risks": [ { "risk": "Phosphoproteomics may have low coverage (e.g., <5,000 phosphopeptides) due to limited starting material.", "probability": "medium", "mitigation": "Pool 3 biological replicates per time point for phosphoproteomics (total 3 mg protein per time point). Use high-pH fractionation to increase coverage." }, { "risk": "DBN inference may be computationally intractable with >10,000 features (phosphopeptides).", "probability": "medium", "mitigation": "Pre-filter phosphopeptides to those with significant temporal variation (ANOVA p<0.01 across time points). Use dimensionality reduction (PCA) to 500 components before DBN." }, { "risk": "Gold-standard network may be incomplete or contain incorrect edges, biasing PR-AUC.", "probability": "high", "mitigation": "Use multiple gold standards (e.g., from STRING, BioGRID, and literature curation). Report PR-AUC against each. Also perform a 'null' validation against a random network of same size." } ] } ], "phase_1_quick_start": { "can_start_today": true, "first_action": "Download the IMP-1710 structure from PubChem (CID: 137321344) and the UCHL1 crystal structure (PDB: 3KVF). Run AutoDock Vina with covalent docking to predict binding pose and estimate kon/koff.", "tools_needed": [ "AutoDock Vina + ADFR", "Python 3.10 with SciPy", "PDB file 3KVF", "IMP-1710 SMILES: CC(C)(C)OC(=O)NC[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc2ccc(cc2)C#C" ], "open_data_sources": [ "PubChem (IMP-1710)", "PDB (3KVF)", "STRING DB v12.0 (https://string-db.org)", "BioGRID (https://thebiogrid.org)" ] } }, "panel": { "reviews": [ { "reviewer_persona": "methodologist", "overall_score": 7.2, "verdict": "accept", "strengths": [ "Le protocole intègre une phase de validation in silico (Phase 1) avec des critères GO/NO-GO explicites, ce qui permet de filtrer les cibles et les conditions avant de s'engager dans des expériences coûteuses, une pratique exemplaire de design expérimental séquentiel.", "La formulation de l'hypothèse est clairement falsifiable avec des prédictions chiffrées (≥90% d'occupation, PR-AUC ≥0.75, ≥50 DEPs) et des H0 bien définies, facilitant l'évaluation objective des résultats.", "L'utilisation de multiples contrôles (DMSO, contrôles de viabilité, validation par réseau gold-standard) et la planification d'une puissance statistique (n=3, 8 time points) montrent une conscience des biais et des exigences de reproductibilité." ], "weaknesses": [ "La dépendance à un réseau gold-standard 'littérature-curé' pour valider l'inférence causale (PR-AUC) est une faiblesse majeure : ce réseau est probablement incomplet, biaisé vers des interactions bien étudiées, et peut contenir des erreurs, ce qui rend la métrique PR-AUC potentiellement trompeuse et non représentative de la vérité terrain.", "Le protocole ne décrit pas de stratégie de randomisation ou d'aveugle pour l'attribution des traitements et l'analyse des données omiques, ce qui expose à des biais de confirmation et de mesure, notamment lors de l'étape d'inférence de réseau où le choix des paramètres du DBN peut être subjectif.", "La puissance statistique annoncée (80% pour un fold-change de 2) est basée sur des données pilotes hypothétiques et ne tient pas compte de la correction pour tests multiples sur des milliers de caractéristiques (protéines, phosphopeptides). Le risque de faux positifs est sous-estimé." ], "critical_questions": [ "Comment comptez-vous valider objectivement le réseau gold-standard utilisé pour le calcul du PR-AUC, et quelle est la stratégie pour traiter le biais de publication inhérent à ce type de réseau ?", "Quel plan de randomisation (par exemple, blocs de temps, randomisation des plaques de culture) et quelles mesures d'aveugle (par exemple, analyste ignorant le traitement) sont prévues pour minimiser les biais de sélection et de mesure dans les phases 2 et 3 ?", "Le protocole mentionne un risque de faible couverture en phosphoprotéomique. Quel est le plan de contingence si le nombre de phosphopeptides quantifiés est insuffisant pour alimenter le modèle DBN (par exemple, < 2000) ?" ], "recommendation": "Ce protocole est bien structuré et montre une bonne compréhension des principes de design expérimental, notamment avec l'approche séquentielle et les critères GO/NO-GO. Cependant, la faiblesse centrale réside dans la validation par un réseau gold-standard biaisé et l'absence de procédures de randomisation/aveugle. Je recommande d'accepter le protocole sous réserve que les auteurs fournissent un plan détaillé pour la construction et la validation indépendante de leur réseau de référence (par exemple, en utilisant des perturbations génétiques indépendantes ou une validation par CRISPR), et qu'ils intègrent explicitement des étapes de randomisation et d'aveugle dans le protocole opérationnel.", "confidence": 0.82 }, { "reviewer_persona": "domain_expert", "overall_score": 6.5, "verdict": "weak_accept", "strengths": [ "L'hypothèse exploite de manière convaincante la spécificité mécanistique des ABPs (inhibition dépendante de l'activité, irréversible) pour créer une perturbation temporellement précise, ce qui est un avantage clair par rapport aux inhibiteurs réversibles ou aux perturbations génétiques qui ont des délais d'action plus longs et moins contrôlables.", "La chaîne causale proposée (inhibition → accumulation de substrat → cascades de signalisation → modélisation ODE/DBN) est logiquement cohérente et s'appuie sur des principes bien établis de biologie des systèmes et de cinétique enzymatique. L'utilisation de données multi-omiques temporelles pour la déconvolution causale est une approche de pointe.", "La base de référence inclut des preuves directes de l'existence d'ABPs sélectifs (ex: UCHL1) et des travaux antérieurs sur l'inférence de réseaux par perturbation (ex: inhibiteurs de kinases, CRISPR), ce qui ancre l'hypothèse dans un contexte de recherche réaliste." ], "weaknesses": [ "L'hypothèse est trop optimiste sur la sélectivité des ABPs. L'affirmation 'selectivity >100-fold over the next closest target' est extrêmement difficile à atteindre pour une sonde covalente dans un contexte cellulaire complexe, et les preuves fournies (IMP-1710) ne démontrent pas une telle sélectivité dans un protéome entier. Les effets hors-cible sont une source majeure de bruit qui peut invalider l'inférence causale.", "Le mécanisme proposé est trop linéaire et ignore la redondance et la plasticité des réseaux de signalisation. L'hypothèse que l'inhibition d'une seule enzyme (ex: UCHL1) produira un signal 'propre' et interprétable est naïve. Les voies compensatoires et les boucles de rétroaction peuvent masquer les effets directs, rendant l'inférence des arêtes causales ambiguë, même avec des modèles ODE.", "Le positionnement par rapport à l'état de l'art est partiellement incorrect. L'inférence de réseaux à partir de données de perturbation omiques est un domaine mature, et le seuil de PR-AUC ≥ 0.75 est arbitraire et très élevé pour des données biologiques réelles, même avec des perturbations idéales. L'hypothèse sous-estime la difficulté de la modélisation et la variance due au contexte cellulaire." ], "critical_questions": [ "Comment l'hypothèse compte-t-elle gérer le problème des effets hors-cible des ABPs, qui sont quasi-inévitables pour les sondes covalentes, et comment distinguer un effet causal direct d'un artefact dû à une réaction croisée avec une cystéine non-ciblée mais fonctionnellement importante ?", "Le modèle suppose un état d'équilibre avant perturbation. Dans un système dynamique comme une cellule vivante, comment garantir que les changements observés sont uniquement dus à l'ABP et non à des oscillations intrinsèques ou à des stress cellulaires (ex: stress du réticulum) induits par la liaison covalente elle-même, indépendamment de l'inhibition de l'activité ?", "Quelle est la stratégie pour valider les arêtes causales inférées ? Sans une validation expérimentale indépendante (ex: mutagenèse, double perturbation), comment être certain que le modèle ne capture pas des corrélations non causales, même avec une intervention temporelle connue ?" ], "recommendation": "L'hypothèse est intellectuellement stimulante et propose une synergie intéressante entre la chimie des sondes et la biologie des systèmes. Cependant, elle repose sur des hypothèses trop fortes concernant la sélectivité des ABPs et la simplicité des réseaux biologiques. Je recommande de reformuler l'hypothèse pour qu'elle soit plus réaliste, en proposant une validation systématique des effets hors-cible (ex: protéomique compétitive) et en utilisant des modèles de réseau plus robustes au bruit. L'acceptation est conditionnelle à une démonstration expérimentale préalable de la sélectivité et de la reproductibilité de l'approche sur un modèle bien caractérisé.", "confidence": 0.8 }, { "reviewer_persona": "contrarian", "overall_score": 2.5, "verdict": "reject", "strengths": [ "L'idée d'utiliser une sonde ABP comme intervention causale temporellement précise est conceptuellement élégante et répond à un vrai besoin méthodologique en inférence de réseaux.", "La formulation explicite des prédictions avec des bornes chiffrées (e.g., PR-AUC ≥ 0.75) est louable et rend l'hypothèse falsifiable en principe." ], "weaknesses": [ "FAIL REASON #1: L'hypothèse d'une sélectivité parfaite de l'ABP (Assumption 2) est intenable. Les données existantes montrent que même des sondes bien caractérisées (comme le cruzain inhibitor, DOI:10.3762/bjoc.9.3) ont des cibles secondaires. IMP-1710 n'a pas été validé en protéomique compétitive à large échelle dans HEK293T. Le moindre off-target sur une kinase ou une déubiquitinase voisine créera un signal de perturbation confondu, rendant l'inférence causale invalide. L'effet mesuré ne sera pas celui de la seule inhibition de UCHL1.", "FAIL REASON #2: L'effet taille attendu sur les omiques est probablement trop faible pour être détecté de manière fiable. UCHL1 est une DUB abondante mais son inhibition aiguë dans une cellule non neuronale (HEK293T, où UCHL1 est peu exprimée) produira un signal de perturbation ténu. La prédiction de ≥50 DEPs à 60 min est irréaliste : la plupart des changements seront des modifications post-traductionnelles transitoires, pas des changements d'abondance protéique. Le bruit technique du TMT masquera ces signaux faibles, conduisant à un réseau inféré dominé par du bruit aléatoire.", "FAIL REASON #3: Le design temporel (8 points sur 120 min) est insuffisant pour capturer la dynamique causale. Les événements de phosphorylation les plus rapides surviennent en 1-2 minutes. Avec un premier point à t=0 et un second à t=15 min (temps de saturation de l'ABP), on rate la fenêtre critique des effets directs. Le modèle ODE ou DBN inférera alors des corrélations entre des points espacés, et non des relations causales. Le PR-AUC ≥ 0.75 est un vœu pieux : dans des réseaux réels (e.g., kinase signaling network, DOI:10.1073/pnas.1423344112), même avec des perturbations bien contrôlées, la PR-AUC dépasse rarement 0.5-0.6." ], "critical_questions": [ "Avez-vous une preuve expérimentale directe, par protéomique de compétition (e.g., ABPP avec enrichissement par click-chemistry), que IMP-1710 à 1 µM dans HEK293T n'a AUCUNE cible secondaire détectable (fold-change < 2, FDR < 0.05) parmi les 5000 protéines les plus abondantes ? Sans cela, l'hypothèse de base est fausse.", "Comment comptez-vous distinguer un effet causal direct de UCHL1 sur son substrat d'un effet indirect via la déstabilisation du protéasome ou le stress du RE, sachant que l'inhibition d'une DUB peut déclencher une réponse au protéasome défectueux en quelques minutes ? Avez-vous inclus un contrôle avec un inhibiteur du protéasome (e.g., MG132) pour démêler ces voies ?" ], "recommendation": "Avant toute soumission, il est impératif de : (1) réaliser un ABPP compétitif complet dans HEK293T pour cartographier les off-targets de IMP-1710 ; (2) démontrer que l'inhibition de UCHL1 dans cette lignée produit un signal omique robuste (≥100 phosphopeptides significatifs à 5 min) ; (3) augmenter la résolution temporelle à 12-15 points incluant t=1, 2, 5, 10 min. Sans ces prérequis, l'hypothèse reste spéculative et non testable.", "confidence": 0.9 }, { "reviewer_persona": "industrialist", "overall_score": 6.5, "verdict": "weak_accept", "strengths": [ "Marche captif et solvable : les grandes pharmas (Novartis, Pfizer, Roche) et biotechs en oncologie/neurodegenerescence (e.g., Alnylam pour les DUBs) paieraient pour valider des cibles enzymatiques orphelines ou deconvoluer des mecanismes de resistance aux inhibiteurs, avec un budget R&D typique de €500k-2M par projet de validation de cible.", "Avantage competitif unique : contrairement aux CRISPR KO (lent, compensatoire) ou aux siRNA (perturbation partielle), un ABP covalent offre une inhibition quasi-instantanee et irreversible, permettant de capturer les effets proximaux (phosphoproteomique precoce) que les autres methodes ratent. C'est un argument de vente fort pour les etudes de signalisation dynamique.", "Faible cout de prototypage : Phase 1 et 2 (€2k-17k) permettent de valider la faisabilite sans investissement massif, ce qui est ideal pour un spin-off ou un projet exploratoire finance par des grants (ERC, BPI France)." ], "weaknesses": [ "Barriere majeure : la specificite des ABP est le talon d'Achille. Pour UCHL1, IMP-1710 est connu pour avoir des cibles secondaires (UCHL3, USP5) a concentrations elevees. Une inhibition >90% en 15 min a 1 µM est optimiste ; le bruit de fond des off-targets pourrait rendre l'inference causale inexploitable (PR-AUC <0.6), ruinant la proposition de valeur.", "Marche de niche, pas de plateforme : l'hypothese est liee a un ABP specifique (UCHL1). Pour etre un produit commercialisable, il faudrait une bibliotheque d'ABP couvrant plusieurs familles d'enzymes (proteases, kinases, etc.). Sans cela, le marche adressable est limite a quelques dizaines de clients academiques et pharma interesses par les DUBs.", "Timeline de commercialisation irrealiste pour un produit : Phase 3 (6-12 mois) ne genere qu'un prototype de preuve de concept. Pour un produit SaaS ou un kit commercial (e.g., ABP + pipeline d'inference cle en main), il faudrait 2-3 ans supplementaires de developpement logiciel, validation sur 5-10 cibles, et gestion reglementaire (IVDR si usage diagnostic)." ], "critical_questions": [ "Quel est le modele de revenu : vente de kits ABP (consommable recurrent) ou licence du logiciel d'inference causale ? Les pharmas preferent des solutions cle en main avec garantie de performance, ce qui implique un cout de validation eleve.", "Comment comptez-vous gerer la competition des plateformes de perturbation multiplexees (e.g., Cellecta's CRISPRi/a barcoded libraries, ou Perturb-seq) qui offrent deja de l'inference causale a l'echelle du genome pour un cout similaire par cible ?", "Quel est le plan d'IP ? Un brevet sur l'utilisation d'ABP pour l'inference causale est probablement invalide face a l'art anterieur (Perturbation + DBN). Un brevet sur le pipeline specifique (e.g., methode de debruitage des off-targets) serait plus defendable mais necessite un algorithme original." ], "recommendation": "Ne pas lancer un produit standalone. A la place, positionner cette approche comme un service de validation de cible (CRO) pour les grandes pharmas, facture €100k-200k par cible. Utiliser les Phases 1-2 comme preuve de concept pour attirer un partenaire pharma (e.g., collaboration avec le groupe DUB de Genentech). Si le PR-AUC >0.75 est atteint, breveter le pipeline de debruitage et licencier le logiciel a une plateforme de CRO existante (e.g., Evotec, Charles River). Le marche est reel mais trop etroit pour justifier un spin-off dedie sans un portefeuille de 10+ ABP valides.", "confidence": 0.75 }, { "reviewer_persona": "funding_strategist", "overall_score": 7.2, "verdict": "accept", "strengths": [ "Hypothèse mécanistiquement élégante et disruptive : utiliser des ABP comme perturbateurs causaux pour l'inférence de réseaux, ce qui dépasse la simple imagerie ou inhibition réversible.", "Protocole clair avec critères GO/NO-GO quantitatifs (occupancy ≥90%, PR-AUC ≥0.75) qui rassure les évaluateurs sur la rigueur méthodologique.", "Cible UCHL1 bien documentée (DUBs, cancer, neurodégénérescence) avec un interactome suffisant pour générer des DEPs, ce qui facilite la validation biologique.", "Approche multi-omique temporelle (transcriptomique, protéomique, métabolomique) alignée sur les priorités de la biologie systémique et de la médecine de précision." ], "weaknesses": [ "TRL actuel très bas (TRL 1-2) : l'hypothèse repose sur une validation in silico et des expériences minimales en cellules HEK293T, sans preuve de faisabilité in vivo ou dans un modèle pathologique.", "Risque élevé de signaux confondants : la sélectivité de l'ABP IMP-1710 pour UCHL1 face aux autres DUBs (ex : USP7, UCHL3) n'est pas démontrée expérimentalement, ce qui pourrait invalider l'inférence causale.", "Consortium non défini : l'hypothèse nécessite des compétences en chimie des ABP, modélisation de réseaux causaux (équations différentielles), et multi-omiques, mais aucun partenaire n'est proposé.", "Budget estimé (€20k-80k) trop faible pour un projet multi-omique complet (séquençage, spectrométrie de masse) et pour un programme européen standard (Horizon Europe exige souvent >€500k)." ], "critical_questions": [ "Quel est le plan pour démontrer la sélectivité de l'ABP contre les principales DUBs humaines (USP7, UCHL3, USP5) avant de lancer la phase multi-omique ? Un panel de 20 DUBs recombinantes est-il envisagé ?", "Comment comptez-vous passer de HEK293T à un modèle pathologique pertinent (ex : cellules cancéreuses avec mutation UCHL1) pour justifier un financement translationnel ?", "Quel est le plan de gestion des données pour les omiques temporelles (format, stockage, partage) afin de satisfaire les exigences de la science ouverte d'Horizon Europe ?" ], "recommendation": "Cibler d'abord un financement exploratoire de type ERC Proof of Concept ou ANR Jeune Chercheur pour valider la sélectivité de l'ABP et la faisabilité de l'inférence causale sur un petit réseau (coût <€150k). En parallèle, soumettre à un appel ERC Starting Grant 2026 avec un consortium incluant un chimiste des ABP et un modélisateur, en ajoutant une validation in vivo sur un modèle murin de glioblastome (UCHL1 surexprimé). Éviter Horizon Europe Cluster 1 (Santé) car le TRL est trop bas ; privilégier le pilier ERC ou un appel MSCA Postdoctoral Fellowship pour un chercheur expérimenté.", "confidence": 0.7, "funding_programs": [ { "program": "ERC Proof of Concept Grant 2025", "agency": "European Research Council", "fit_score": 0.85, "typical_budget": "€150,000 (forfaitaire)", "success_rate": "~40% (sur éligibles)", "next_deadline": "Mars 2025 (première session)", "rationale": "Ce programme finance la validation de concepts à haut risque issus de recherches ERC antérieures. L'hypothèse ABP comme perturbateur causal est exactement le type d'idée 'proof of concept' qui peut être testée rapidement (8-14 mois) avec un budget modeste. Idéal pour démontrer la sélectivité et l'inférence sur un petit réseau, sans nécessiter de consortium." }, { "program": "ANR Jeune Chercheur (JCJC) 2025", "agency": "Agence Nationale de la Recherche (France)", "fit_score": 0.8, "typical_budget": "€150k - €300k", "success_rate": "~18% (toutes disciplines)", "next_deadline": "Octobre 2025 (générique)", "rationale": "L'ANR JCJC est adapté à un porteur de projet junior (max 10 ans après thèse) avec une idée originale. Le budget permet de couvrir la synthèse de l'ABP, les tests de sélectivité, et une première série d'omiques (transcriptomique + protéomique) sur HEK293T. Le caractère interdisciplinaire (chimie, biologie, modélisation) est un atout pour l'évaluation ANR." }, { "program": "MSCA Postdoctoral Fellowship 2025 (Global Fellowship)", "agency": "European Commission (Horizon Europe)", "fit_score": 0.7, "typical_budget": "€200k - €250k (pour 2-3 ans)", "success_rate": "~15% (2023)", "next_deadline": "Septembre 2025", "rationale": "Ce programme finance un chercheur postdoctoral pour mener un projet de recherche dans un pays tiers (ex : USA) avec retour en Europe. L'hypothèse pourrait être portée par un postdoc ayant une double compétence en chimie des ABP et en biologie systémique. Le Global Fellowship permettrait de collaborer avec un labo américain expert en modélisation de réseaux (ex : MIT, Stanford) pour la phase d'inférence causale, puis de revenir en Europe pour la validation in vivo." } ] } ], "meta_review": { "consensus_score": 5.86, "verdict": "publish_brief", "key_consensus": [ "L'utilisation d'ABP comme perturbateurs causaux temporellement précis est conceptuellement élégante et répond à un besoin méthodologique réel en inférence de réseaux.", "La formulation explicite de prédictions chiffrées (≥90% d'occupation, PR-AUC ≥0.75, ≥50 DEPs) et de critères GO/NO-GO est une force méthodologique qui rend l'hypothèse falsifiable.", "La sélectivité des ABP est unanimement identifiée comme le talon d'Achille critique : les effets hors-cible quasi-inévitables des sondes covalentes menacent directement la validité de l'inférence causale.", "Le design temporel actuel (8 points sur 120 min) est jugé insuffisant par plusieurs reviewers pour capturer la dynamique causale rapide des événements de signalisation." ], "key_disagreements": [ "Le Contrarian (score 2.5, confiance 0.9) considère l'hypothèse comme non testable et rejette catégoriquement, tandis que les autres reviewers (scores 6.5-7.2) voient un potentiel significatif malgré des réserves majeures.", "Désaccord sur la faisabilité d'atteindre PR-AUC ≥0.75 : le Contrarian et le Domain Expert estiment ce seuil irréaliste (<0.5-0.6 dans les réseaux réels), tandis que le Methodologist et le Funding Strategist le considèrent comme un objectif ambitieux mais défendable.", "Le Domain Expert et l'Industrialist jugent le marché trop étroit pour un produit standalone, alors que le Funding Strategist voit un potentiel de financement ERC/ANR pour un projet exploratoire.", "Désaccord sur la puissance du signal omique attendu : le Contrarian prédit un signal trop faible dans HEK293T (UCHL1 peu exprimée), tandis que le Domain Expert et le Funding Strategist estiment que l'interactome de UCHL1 est suffisant." ], "critical_path": "La démonstration expérimentale irréfutable de la sélectivité de l'ABP IMP-1710 (ou d'un ABP alternatif) par protéomique de compétition à large échelle dans le système cellulaire choisi, couplée à une validation que l'inhibition de UCHL1 produit un signal omique robuste et reproductible (≥100 phosphopeptides significatifs à des temps précoces <15 min), constitue le prérequis absolu sans lequel l'hypothèse entière s'effondre.", "final_recommendation": "L'hypothèse est intellectuellement prometteuse mais immature. Le panel recommande une révision majeure avant resoumission. Les auteurs doivent : (1) fournir des données de protéomique compétitive démontrant la sélectivité de l'ABP dans le système cellulaire cible ; (2) augmenter la résolution temporelle à 12-15 points incluant des temps <5 min ; (3) démontrer un signal omique précoce robuste sur un modèle bien caractérisé ; (4) intégrer des contrôles pour les voies compensatoires (ex : inhibiteur du protéasome). Sans ces prérequis, l'hypothèse reste spéculative et ne peut être publiée dans un journal de premier plan.", "brief_quality_gate": false, "revision_guidance": [ "Réaliser un ABPP compétitif complet dans HEK293T (ou lignée pertinente) pour cartographier les off-targets de IMP-1710 à 1 µM, avec un seuil de détection <2% d'occupation sur les cibles secondaires.", "Augmenter la résolution temporelle à 12-15 points incluant t=1, 2, 5, 10, 15, 30, 45, 60, 90, 120 min pour capturer la dynamique causale rapide.", "Démontrer que l'inhibition de UCHL1 produit ≥100 phosphopeptides significatifs (FDR<0.05) dès 5-15 min post-traitement, avec un contrôle MG132 pour démêler les effets du stress du protéasome.", "Ajouter une stratégie de randomisation et d'aveugle explicite pour l'attribution des traitements et l'analyse des données omiques.", "Proposer un plan de validation indépendante des arêtes causales inférées (ex : double perturbation, mutagenèse dirigée, ou validation par CRISPR).", "Reformuler l'hypothèse pour intégrer explicitement la gestion des effets hors-cible (modélisation de bruit, débruitage algorithmique) et abaisser le seuil PR-AUC à ≥0.6 pour refléter la réalité des réseaux biologiques." ], "llm_verdict": "revise_and_resubmit", "llm_consensus_score": 6.7, "verdict_override_reason": "Python threshold override: consensus 5.86 at iter 2 → publish_brief (LLM said revise_and_resubmit)" } }, "vulgarization_fr": { "title_fr": "Piéger une enzyme pour cartographier son réseau d'influence dans la cellule", "hypothesis_in_brief": "Comment une enzyme particulière influence-t-elle le comportement de toute une cellule ? Pour le découvrir, cette hypothèse propose de la neutraliser très rapidement et de façon irréversible, puis d'observer les conséquences en chaîne sur l'ensemble des molécules de la cellule (ARN, protéines, métabolites). En mesurant ces changements minute par minute, l'approche vise à reconstruire le plan de câblage de son réseau d'action, en distinguant les effets directs des effets indirects.", "why_it_matters": "Comprendre le réseau d'influence d'une enzyme est crucial pour savoir ce qui se dérègle dans une maladie. Les méthodes actuelles (comme supprimer le gène de l'enzyme) sont lentes : la cellule a le temps de s'adapter, brouillant les pistes. Cette approche permettrait d'obtenir une photographie nette et immédiate de l'effet d'une enzyme, ouvrant la voie à des diagnostics plus précis et à l'identification de nouvelles cibles pour des médicaments, en particulier dans le cancer ou les maladies neurodégénératives.", "imagine_that": "Imaginez que vous voulez comprendre le rôle exact d'un interrupteur dans le réseau électrique d'un immeuble. Si vous coupez le courant général, tout s'éteint et vous ne savez pas quel circuit l'interrupteur commande. En revanche, si vous pouvez, en une seconde, désactiver proprement et uniquement cet interrupteur, puis regarder, lampe par lampe, ce qui s'éteint et ce qui reste allumé, vous pouvez tracer son influence exacte. L'hypothèse fonctionne sur le même principe : une sonde chimique joue le rôle d'un 'coupe-circuit' ultra-spécifique pour une enzyme.", "concretely": { "intro": "Pour vérifier l'hypothèse, un protocole en trois phases, de l'ordinateur au laboratoire, est proposé.", "phase1": "D'abord, une simulation sur ordinateur vérifie que la sonde chimique choisie (IMP-1710) peut bien se fixer sur l'enzyme cible (UCHL1) sans accrocher d'autres enzymes, ce qui fausserait les résultats.", "phase2": "Ensuite, une expérience en laboratoire sur des cellules humaines (HEK293T) confirme que la sonde neutralise bien l'enzyme à 95% en moins de 15 minutes, sans tuer les cellules, et que les premières conséquences sont détectables.", "phase3": "Enfin, une expérience à grande échelle mesure l'évolution de milliers de molécules (ARN, protéines, métabolites) à huit moments différents après l'inhibition. Ces données sont ensuite analysées par un modèle mathématique pour reconstruire le réseau causal de l'enzyme." }, "reviewers_say": "Le panel de relecteurs est partagé. La majorité salue l'élégance conceptuelle et la rigueur du protocole, avec des prédictions chiffrées claires. Mais un avis très critique juge l'hypothèse irréaliste : il est extrêmement difficile de garantir qu'une sonde chimique n'agit que sur une seule enzyme dans une cellule vivante, et le signal biologique attendu pourrait être trop faible pour être fiable. Le consensus est que l'idée est prometteuse mais immature. Pour convaincre, il faudrait d'abord prouver expérimentalement la sélectivité parfaite de la sonde dans le type cellulaire utilisé." }, "vulgarization_en": { "title": "Trapping an enzyme to map its network of influence within the cell", "hypothesis_in_brief": "How does a particular enzyme influence the behaviour of an entire cell? To address this, the hypothesis proposes neutralising it rapidly and irreversibly, then observing the cascade of consequences across all molecules in the cell (RNA, proteins, metabolites). By measuring these changes minute by minute, the approach aims to reconstruct the wiring diagram of its action network, distinguishing direct effects from indirect ones.", "why_it_matters": "Understanding the network of influence of an enzyme is crucial for determining what goes awry in a disease. Current methods (such as deleting the enzyme’s gene) are slow: the cell has time to adapt, blurring the trail. This approach would yield a clear and immediate snapshot of an enzyme’s effect, paving the way for more precise diagnostics and the identification of new drug targets, particularly in cancer or neurodegenerative diseases.", "imagine_that": "Imagine that you wish to understand the precise role of a switch in a building’s electrical network. If you cut the main power, everything goes dark and you cannot tell which circuit the switch controls. If, however, you can, in one second, cleanly and exclusively deactivate that one switch, then examine, lamp by lamp, what turns off and what stays lit, you can trace its exact influence. The hypothesis works on the same principle: a chemical probe acts as an ultra-specific ‘circuit-breaker’ for a single enzyme.", "reviewers_say": "The panel of reviewers is divided. The majority commend the conceptual elegance and the rigour of the protocol, with clear quantitative predictions. However, one highly critical opinion deems the hypothesis unrealistic: it is extremely difficult to guarantee that a chemical probe acts on only one enzyme within a living cell, and the expected biological signal may be too weak to be reliable. The consensus is that the idea is promising but immature. To be convincing, the perfect selectivity of the probe in the cell type used would first need to be demonstrated experimentally.", "concretely": { "intro": "To test the hypothesis, a three-phase protocol, from computer to laboratory, is proposed.", "phase1": "First, a computer simulation verifies that the selected chemical probe (IMP-1710) can bind to the target enzyme (UCHL1) without attaching to other enzymes, which would distort the results.", "phase2": "Subsequently, a laboratory experiment on human cells (HEK293T) confirms that the probe neutralises the enzyme by 95% in under 15 minutes, without killing the cells, and that the initial consequences are detectable.", "phase3": "Finally, a large-scale experiment measures the evolution of thousands of molecules (RNA, proteins, metabolites) at eight distinct time points after inhibition. These data are then analysed by a mathematical model to reconstruct the causal network of the enzyme." } }, "panel_en": { "reviews": [ { "reviewer_persona": "methodologist", "overall_score": 7.2, "verdict": "accept", "confidence": 0.82, "strengths": [ "The protocol incorporates an in silico validation phase (Phase 1) with explicit GO/NO-GO criteria, which permits the filtering of targets and conditions before commitment to costly experiments — a best practice in sequential experimental design.", "The hypothesis formulation is clearly falsifiable, with quantified predictions (≥90% occupancy, PR-AUC ≥0.75, ≥50 DEPs) and well-defined H0, facilitating objective evaluation of the results.", "The use of multiple controls (DMSO, viability controls, gold-standard network validation) and the planning of statistical power (n=3, 8 time points) demonstrate an awareness of biases and reproducibility requirements." ], "weaknesses": [ "The reliance on a gold-standard 'literature-curated' network to validate causal inference (PR-AUC) is a major weakness: this network is likely incomplete, biased towards well-studied interactions, and may contain errors, rendering the PR-AUC metric potentially misleading and unrepresentative of the ground truth.", "The protocol does not describe a strategy for randomisation or blinding in treatment assignment and omics data analysis, exposing the study to confirmation and measurement biases, particularly during the network inference step where the choice of DBN parameters may be subjective.", "The stated statistical power (80% for a 2-fold change) is based on hypothetical pilot data and does not account for correction for multiple testing across thousands of features (proteins, phosphopeptides). The risk of false positives is underestimated." ], "critical_questions": [ "How does the panel intend to objectively validate the gold-standard network used for the PR-AUC calculation, and what is the strategy for addressing the publication bias inherent to this type of network?", "What randomisation plan (for example, time blocks, randomisation of culture plates) and what blinding measures (for example, an analyst unaware of the treatment) are planned to minimise selection and measurement biases in Phases 2 and 3?", "The protocol mentions a risk of low phosphoproteomic coverage. What is the contingency plan if the number of quantified phosphopeptides is insufficient to feed the DBN model (for example, < 2000)?" ], "recommendation": "This protocol is well structured and demonstrates a sound understanding of experimental design principles, particularly with the sequential approach and the GO/NO-GO criteria. However, the central weakness lies in the validation using a biased gold-standard network and the absence of randomisation and blinding procedures. The panel recommends acceptance of the protocol on the condition that the authors provide a detailed plan for the construction and independent validation of their reference network (for example, by using independent genetic perturbations or CRISPR-based validation), and that they explicitly incorporate randomisation and blinding steps into the operational protocol." }, { "reviewer_persona": "domain_expert", "overall_score": 6.5, "verdict": "weak_accept", "confidence": 0.8, "strengths": [ "The hypothesis convincingly exploits the mechanistic specificity of ABPs (activity-dependent, irreversible inhibition) to create a temporally precise perturbation, which is a clear advantage over reversible inhibitors or genetic perturbations that have longer and less controllable delays in action.", "The proposed causal chain (inhibition → substrate accumulation → signalling cascades → ODE/DBN modelling) is logically coherent and rests on well-established principles of systems biology and enzyme kinetics. The use of temporal multi-omic data for causal deconvolution is a state-of-the-art approach.", "The baseline includes direct evidence for the existence of selective ABPs (e.g., UCHL1) and prior work on network inference by perturbation (e.g., kinase inhibitors, CRISPR), which anchors the hypothesis in a realistic research context." ], "weaknesses": [ "The hypothesis is judged to be overly optimistic regarding the selectivity of the ABPs. The claim ‘selectivity >100-fold over the next closest target’ is considered extremely difficult to achieve for a covalent probe in a complex cellular context, and the evidence provided (IMP-1710) does not demonstrate such selectivity across an entire proteome. Off-target effects represent a major source of noise that can invalidate causal inference.", "The proposed mechanism is regarded as excessively linear and ignores the redundancy and plasticity of signalling networks. The hypothesis that inhibition of a single enzyme (e.g., UCHL1) will produce a ‘clean’ and interpretable signal is judged to be naive. Compensatory pathways and feedback loops can mask direct effects, rendering the inference of causal edges ambiguous, even with ODE models.", "The positioning relative to the state of the art is considered partially incorrect. Network inference from omics perturbation data is a mature domain, and the PR-AUC threshold of ≥ 0.75 is arbitrary and very high for real biological data, even under ideal perturbations. The hypothesis underestimates the difficulty of modelling and the variance attributable to cellular context." ], "critical_questions": [ "How does the hypothesis intend to address the problem of off-target effects of ABPs, which are nearly unavoidable for covalent probes, and how is a direct causal effect distinguished from an artefact arising from cross-reactivity with a non-targeted but functionally important cysteine?", "The model assumes an equilibrium state prior to perturbation. In a dynamic system such as a living cell, how is it ensured that the observed changes are attributable solely to the ABP and not to intrinsic oscillations or cellular stresses (e.g., reticulum stress) induced by the covalent binding itself, independently of activity inhibition?", "What is the strategy for validating the inferred causal edges? Without independent experimental validation (e.g., mutagenesis, double perturbation), how is it certain that the model does not capture non-causal correlations, even with a known temporal intervention?" ], "recommendation": "The hypothesis is intellectually stimulating and proposes an interesting synergy between probe chemistry and systems biology. However, it rests on overly strong assumptions concerning the selectivity of ABPs and the simplicity of biological networks. The panel recommends that the hypothesis be reformulated to be more realistic, by proposing a systematic validation of off-target effects (e.g., competitive proteomics) and by using network models that are more robust to noise. Acceptance is conditional upon prior experimental demonstration of the selectivity and reproducibility of the approach on a well-characterised model." }, { "reviewer_persona": "contrarian", "overall_score": 2.5, "verdict": "reject", "confidence": 0.9, "strengths": [ "The idea of using an ABP probe as a temporally precise causal intervention is conceptually elegant and addresses a genuine methodological need in network inference.", "The explicit formulation of predictions with numerical bounds (e.g., PR-AUC ≥ 0.75) is commendable and renders the hypothesis falsifiable in principle." ], "weaknesses": [ "FAIL REASON #1: The hypothesis of perfect selectivity for the ABP (Assumption 2) is untenable. Existing data show that even well-characterised probes (such as the cruzain inhibitor, DOI:10.3762/bjoc.9.3) have secondary targets. IMP-1710 has not been validated in large-scale competitive proteomics in HEK293T. Any off-target effect on a neighbouring kinase or deubiquitinase will generate a confounded perturbation signal, rendering causal inference invalid. The measured effect will not be that of UCHL1 inhibition alone.", "FAIL REASON #2: The expected effect size on the omics data is probably too small to be detected reliably. UCHL1 is an abundant DUB, but its acute inhibition in a non-neuronal cell (HEK293T, where UCHL1 is weakly expressed) will produce a faint perturbation signal. The prediction of ≥50 DEPs at 60 min is unrealistic: most changes will be transient post-translational modifications, not changes in protein abundance. Technical noise from TMT will mask these weak signals, leading to an inferred network dominated by random noise.", "FAIL REASON #3: The temporal design (8 time points over 120 min) is insufficient to capture causal dynamics. The fastest phosphorylation events occur within 1–2 minutes. With a first time point at t=0 and a second at t=15 min (the saturation time of the ABP), the critical window for direct effects is missed. The ODE or DBN model will then infer correlations between spaced time points, not causal relationships. A PR-AUC ≥ 0.75 is wishful thinking: in real networks (e.g., kinase signalling network, DOI:10.1073/pnas.1423344112), even with well-controlled perturbations, the PR-AUC rarely exceeds 0.5–0.6." ], "critical_questions": [ "Is there direct experimental evidence, by competitive proteomics (e.g., ABPP with click-chemistry enrichment), that IMP-1710 at 1 µM in HEK293T has NO detectable secondary target (fold-change < 2, FDR < 0.05) among the 5,000 most abundant proteins? Without this, the underlying hypothesis is invalid.", "How does the panel plan to distinguish a direct causal effect of UCHL1 on its substrate from an indirect effect via proteasome destabilisation or ER stress, given that inhibition of a DUB can trigger a defective proteasome response within minutes? Was a control with a proteasome inhibitor (e.g., MG132) included to disentangle these pathways?" ], "recommendation": "Before any submission, it is imperative that: (1) a competitive ABPP be performed in HEK293T to map the off-targets of IMP-1710; (2) inhibition of UCHL1 in this line be demonstrated to produce a robust omic signal (≥100 significant phosphopeptides at 5 min); (3) temporal resolution be increased to 12–15 points including t=1, 2, 5, 10 min. Without these prerequisites, the hypothesis remains speculative and untestable." }, { "reviewer_persona": "industrialist", "overall_score": 6.5, "verdict": "weak_accept", "confidence": 0.75, "strengths": [ "Captive and solvent market: large pharmaceutical companies (Novartis, Pfizer, Roche) and biotechs in oncology/neurodegeneration (e.g., Alnylam for DUBs) would pay to validate orphan enzymatic targets or to deconvolute mechanisms of resistance to inhibitors, with a typical R&D budget of €500k–2M per target validation project.", "Unique competitive advantage: unlike CRISPR KO (slow, compensatory) or siRNA (partial perturbation), a covalent ABP provides near-instantaneous and irreversible inhibition, enabling the capture of proximal effects (early phosphoproteomics) that other methods miss. This constitutes a strong selling point for dynamic signalling studies.", "Low prototyping cost: Phase 1 and Phase 2 (€2k–17k) allow feasibility to be validated without substantial investment, which is ideal for a spin-off or an exploratory project funded by grants (ERC, BPI France)." ], "weaknesses": [ "Major barrier: the specificity of ABPs is the Achilles heel. For UCHL1, IMP-1710 is known to have secondary targets (UCHL3, USP5) at elevated concentrations. An inhibition of >90% in 15 min at 1 µM is optimistic; the background noise from off-targets could render causal inference unusable (PR-AUC <0.6), undermining the value proposition.", "Niche market, not a platform: the hypothesis is tied to a specific ABP (UCHL1). To be a marketable product, a library of ABPs covering several enzyme families (proteases, kinases, etc.) would be required. Without this, the addressable market is limited to a few dozen academic and pharma clients interested in DUBs.", "Commercialisation timeline unrealistic for a product: Phase 3 (6–12 months) generates only a proof-of-concept prototype. For a SaaS product or a commercial kit (e.g., ABP plus a turnkey inference pipeline), an additional 2–3 years of software development, validation on 5–10 targets, and regulatory management (IVDR if for diagnostic use) would be required." ], "critical_questions": [ "What is the revenue model: sale of ABP kits (recurrent consumable) or licensing of the causal inference software? Pharmaceutical companies prefer turnkey solutions with performance guarantees, which implies a high validation cost.", "How does the panel plan to manage competition from multiplexed perturbation platforms (e.g., Cellecta's CRISPRi/a barcoded libraries, or Perturb-seq) that already offer genome-scale causal inference at a similar cost per target?", "What is the intellectual property plan? A patent on the use of ABP for causal inference is likely invalid in light of prior art (perturbation + DBN). A patent on the specific pipeline (e.g., a method for de-noising off-target effects) would be more defensible but requires an original algorithm." ], "recommendation": "The product should not be launched as a standalone offering. Instead, this approach is positioned as a target validation service (CRO) for large pharmaceutical companies, invoiced at €100k–200k per target. Phases 1–2 are used as proof of concept to attract a pharmaceutical partner (e.g., collaboration with the DUB group at Genentech). If a PR-AUC >0.75 is achieved, the denoising pipeline is patented and the software is licensed to an existing CRO platform (e.g., Evotec, Charles River). The market is real but too narrow to justify a dedicated spin-off without a portfolio of 10 or more validated ABPs." }, { "reviewer_persona": "funding_strategist", "overall_score": 7.2, "verdict": "accept", "confidence": 0.7, "funding_programs": [ { "program": "ERC Proof of Concept Grant 2025", "agency": "European Research Council", "fit_score": 0.85, "typical_budget": "€150,000 (forfaitaire)", "success_rate": "~40% (sur éligibles)", "next_deadline": "Mars 2025 (première session)", "rationale": "Ce programme finance la validation de concepts à haut risque issus de recherches ERC antérieures. L'hypothèse ABP comme perturbateur causal est exactement le type d'idée 'proof of concept' qui peut être testée rapidement (8-14 mois) avec un budget modeste. Idéal pour démontrer la sélectivité et l'inférence sur un petit réseau, sans nécessiter de consortium." }, { "program": "ANR Jeune Chercheur (JCJC) 2025", "agency": "Agence Nationale de la Recherche (France)", "fit_score": 0.8, "typical_budget": "€150k - €300k", "success_rate": "~18% (toutes disciplines)", "next_deadline": "Octobre 2025 (générique)", "rationale": "L'ANR JCJC est adapté à un porteur de projet junior (max 10 ans après thèse) avec une idée originale. Le budget permet de couvrir la synthèse de l'ABP, les tests de sélectivité, et une première série d'omiques (transcriptomique + protéomique) sur HEK293T. Le caractère interdisciplinaire (chimie, biologie, modélisation) est un atout pour l'évaluation ANR." }, { "program": "MSCA Postdoctoral Fellowship 2025 (Global Fellowship)", "agency": "European Commission (Horizon Europe)", "fit_score": 0.7, "typical_budget": "€200k - €250k (pour 2-3 ans)", "success_rate": "~15% (2023)", "next_deadline": "Septembre 2025", "rationale": "Ce programme finance un chercheur postdoctoral pour mener un projet de recherche dans un pays tiers (ex : USA) avec retour en Europe. L'hypothèse pourrait être portée par un postdoc ayant une double compétence en chimie des ABP et en biologie systémique. Le Global Fellowship permettrait de collaborer avec un labo américain expert en modélisation de réseaux (ex : MIT, Stanford) pour la phase d'inférence causale, puis de revenir en Europe pour la validation in vivo." } ], "strengths": [ "A mechanistically elegant and disruptive hypothesis is proposed: the use of ABPs as causal perturbagens for network inference, moving beyond simple imaging or reversible inhibition.", "A clear protocol is provided with quantitative GO/NO-GO criteria (occupancy ≥90%, PR-AUC ≥0.75), which reassures reviewers regarding methodological rigour.", "The UCHL1 target is well documented (DUBs, cancer, neurodegeneration) and possesses a sufficient interactome to generate DEPs, thereby facilitating biological validation.", "A temporal multi-omic approach (transcriptomic, proteomic, metabolomic) is aligned with the priorities of systems biology and precision medicine." ], "weaknesses": [ "Current TRL very low (TRL 1–2): the hypothesis rests on in silico validation and minimal experiments in HEK293T cells, with no evidence of feasibility in vivo or in a pathological model.", "High risk of confounding signals: the selectivity of the ABP IMP-1710 for UCHL1 over other DUBs (e.g., USP7, UCHL3) is not demonstrated experimentally, which could invalidate the causal inference.", "Consortium not defined: the hypothesis requires expertise in ABP chemistry, causal network modelling (differential equations), and multi-omics, yet no partner is proposed.", "Estimated budget (€20k–80k) is too low for a complete multi-omics project (sequencing, mass spectrometry) and for a standard European programme (Horizon Europe often requires >€500k)." ], "critical_questions": [ "What is the plan to demonstrate the selectivity of the ABP against the principal human DUBs (USP7, UCHL3, USP5) before launching the multi-omic phase? Is a panel of 20 recombinant DUBs envisaged?", "How is the transition from HEK293T to a relevant pathological model (e.g., cancer cells harbouring a UCHL1 mutation) to be accomplished in order to justify translational funding?", "What is the data management plan for the temporal omics (format, storage, sharing) to satisfy the open science requirements of Horizon Europe?" ], "recommendation": "Exploratory funding of the ERC Proof of Concept or ANR Jeune Chercheur type should first be targeted to validate ABP selectivity and the feasibility of causal inference on a small network (cost <€150k). In parallel, a submission should be made to the ERC Starting Grant 2026 call with a consortium that includes an ABP chemist and a modeller, adding an in vivo validation on a murine glioblastoma model (UCHL1 overexpressed). Horizon Europe Cluster 1 (Health) should be avoided, as the TRL is too low; the ERC pillar or an MSCA Postdoctoral Fellowship call for an experienced researcher should be favoured instead." } ], "meta_review": { "consensus_score": 5.86, "verdict": "publish_brief", "brief_quality_gate": false, "llm_verdict": "revise_and_resubmit", "llm_consensus_score": 6.7, "verdict_override_reason": "Python threshold override: consensus 5.86 at iter 2 → publish_brief (LLM said revise_and_resubmit)", "key_consensus": [ "The use of ABPs as temporally precise causal perturbagens is conceptually elegant and addresses a genuine methodological need in network inference.", "The explicit formulation of quantitative predictions (≥90% occupancy, PR-AUC ≥0.75, ≥50 DEPs) and GO/NO-GO criteria is a methodological strength that renders the hypothesis falsifiable.", "ABP selectivity is unanimously identified as the critical Achilles heel: the near-inevitable off-target effects of covalent probes directly threaten the validity of causal inference.", "The current temporal design (8 time points over 120 min) is judged by several reviewers to be insufficient for capturing the rapid causal dynamics of signalling events." ], "key_disagreements": [ "The Contrarian (score 2.5, confidence 0.9) judges the hypothesis to be untestable and rejects it outright, whereas the other reviewers (scores 6.5–7.2) see significant potential despite major reservations.", "Disagreement is noted regarding the feasibility of achieving PR-AUC ≥0.75: the Contrarian and the Domain Expert consider this threshold unrealistic (<0.5–0.6 in real networks), while the Methodologist and the Funding Strategist regard it as an ambitious but defensible target.", "The Domain Expert and the Industrialist judge the market to be too narrow for a standalone product, whereas the Funding Strategist sees potential for ERC/ANR funding for an exploratory project.", "Disagreement is noted regarding the strength of the expected omic signal: the Contrarian predicts a signal too weak in HEK293T (UCHL1 being poorly expressed), whereas the Domain Expert and the Funding Strategist consider the UCHL1 interactome to be sufficient." ], "revision_guidance": [ "A competitive ABPP assay is to be performed in HEK293T (or a relevant cell line) to map the off-targets of IMP-1710 at 1 µM, with a detection threshold of <2% occupancy on secondary targets.", "The temporal resolution is to be increased to 12–15 time points including t = 1, 2, 5, 10, 15, 30, 45, 60, 90, 120 min to capture rapid causal dynamics.", "It is to be demonstrated that inhibition of UCHL1 yields ≥100 significant phosphopeptides (FDR < 0.05) within 5–15 min post-treatment, with an MG132 control to disentangle proteasome stress effects.", "An explicit randomisation and blinding strategy is to be added for treatment allocation and omics data analysis.", "An independent validation plan for the inferred causal edges is to be proposed (e.g., double perturbation, directed mutagenesis, or CRISPR validation).", "The hypothesis is to be reformulated to explicitly incorporate off-target effect management (noise modelling, algorithmic denoising) and the PR-AUC threshold is to be lowered to ≥0.6 to reflect the reality of biological networks." ], "critical_path": "The absolute prerequisite, without which the entire hypothesis collapses, is the irrefutable experimental demonstration of the selectivity of the ABP IMP-1710 (or an alternative ABP) through large-scale competition proteomics in the chosen cellular system, coupled with a validation that the inhibition of UCHL1 produces a robust and reproducible omic signal (≥100 significant phosphopeptides at early time points <15 min).", "final_recommendation": "The hypothesis is judged intellectually promising but immature. The panel recommends major revision before resubmission. The authors are required to: (1) provide competitive proteomics data demonstrating ABP selectivity in the target cellular system; (2) increase the temporal resolution to 12–15 points, including time points <5 min; (3) demonstrate a robust early omic signal in a well-characterised model; (4) integrate controls for compensatory pathways (e.g., proteasome inhibitor). Without these prerequisites, the hypothesis remains speculative and cannot be published in a leading journal." } } }